An analysis of the complete Molluscum contagiosum virus (MCV-1) genome sequence revealed a 104-amino-acid open reading frame (MC148R) that is structurally related to the ␤ (CC) family of chemokines. The predicted MCV chemokine homolog (MCCH) has a deletion in the NH2-terminal activation domain, suggesting the absence of chemoattractant activity. The principal objectives of the present study were to determine whether: (i) MCCH is conserved in independent isolates of MCV-1 and MCV-2; (ii) MCCH mRNA is expressed in vivo; and (iii) the MCCH protein is secreted from mammalian cells. The nucleotide sequence of the MCCH gene locus was determined for 27 isolates of MCV-1 and 2 of MCV-2 obtained from 29 MCV-infected individuals. In each case, the characteristic CC sequence, the NH2-terminal deletion, and the length of the open reading frame were conserved, although there were some, mostly conservative, amino acid substitutions. Since MCV cannot be propagated in cell culture, mRNA was synthesized in vitro by the early transcription apparatus in purified MCV virions. MCCH RNA was amplified by RT±PCR; the sequence included the complete open reading frame and extended 40 to 50 nucleotides past the first poxviral termination signal (TTTTTNT). Similar RT±PCR results were obtained using total cellular RNA derived from MCV-infected tissue specimens. Finally, the MCCH open reading frame was expressed in a vaccinia virus vector and the predicted size polypeptide was secreted into the medium, as determined by Western blotting. Taken together, our data support the prediction that MCV expresses a secreted chemokine homolog that could antagonize the inflammatory response in vivo.
INTRODUCTION
Molluscum contagiosum virus (MCV) and variola (smallpox) virus are the only known poxviruses that are specific for the human host. In contrast to the acute generalized infection with high mortality caused by variola virus, MCV produces a chronic infection that is localized to epidermal tissue (Postlethwaite, 1970; Epstein, 1992) .
One of the most interesting findings, from the analysis of the 190,289-bp MCV genome sequence (Senkevich et al., 1996 (Senkevich et al., , 1997 , was the identification of a putative gene product (MC148R, 104 amino acids, genomic nucleotide position 166,992 to 167,303) with homology to members of the ␤ or CC family of chemokines. Chemokines are involved in leukocyte trafficking by specifically mediating attachment of leukocytes to the vascular endothelium, leukocyte activation, and diapedesis (Ben-Baruch et al., 1995; Omz et al., 1996) . It was noted, however, that the predicted MCV chemokine homolog (MCCH) had an apparent deletion in the NH2-terminal region that is required for chemokine activation of cells (Senkevich et al., 1996) . Consequently, it was suggested that the MCCH might act as a cellular chemokine antagonist. Such a role could explain histological data indicating the absence of mononuclear cells from early MC lesions (Heng et al., 1989; Viac and Chardonnet, 1990) .
To be consistent with a role in preventing inflammation (i) the MCCH sequence with the noted NH2-terminal deletion should be generally present in MCV isolates; (ii) the predicted open reading frame should be transcribed in vivo; and (iii) the expressed protein should be secreted from infected cells. To answer the first question, it was necessary to determine the primary structure of MCCH genes from independent MCV isolates. The other questions were difficult to answer because MCV has never been grown in cell culture and it replicates insufficiently only in athymic mice containing human skin xenotransplants (Buller et al., 1995) . Evidence for transcription of the MCCH gene was obtained in two ways. The first took advantage of the fact that permeabilized poxvirus particles are able to synthesize 5Ј -capped, polyadenylated, and translatable mRNA in vitro. This is possible because the virions carry a DNA-dependent RNA polymerase, early transcription factor, poly(A) polymerase, and cap-ping enzyme (Kates and McAuslan, 1967; Munyon et al., 1967; Shand et al., 1976) . The mRNAs synthesized within the virus particles are of the early temporal class because only the early transcription factor is present (Broyles et al., 1988) . The second method was to perform reverse transcriptase (RT)±PCR on material obtained from clinical speciments. Finally, we used a vaccinia virus expression vector to demonstrate that the protein is secreted from mammalian cells.
RESULTS

Conservation of the MCCH in independent MCV-1 and MCV-2 isolates
The MCCH gene locus of 29 independent MCV isolates was analyzed by DNA nucleotide sequencing. Based on restriction enzyme analysis of genomic DNA (Darai et al., 1986) , 27 of these isolates were identified genetically as MCV-1 and the remaining 2 isolates were of MCV-2 origin. Oligonucleotide primers 1 and 2 (Table  1) were used to amplify 570 bp of the MCCH gene locus. The primers 1 and 2 correspond to nucleotide positions 130 nucleotides upstream of the initiation codon and 75 nucleotides downstream of the stopcodon, respectively (Fig. 1) . The analysis of the DNA sequences of the amplified DNA products revealed that each MCV isolate contained an intact MCCH coding region 312 nucleotides in length, encoding a polypeptide of 104 amino acid residues. The DNA sequences of the MCCH genes derived from 24 of the 29 MCV isolates were found to be identical to the DNA sequences of the MCCH gene of the prototype virus isolate (MCV 1/80; GenBank Accession No. U60315 (Senkevich et al., 1996 (Senkevich et al., , 1997 ). The results of this study are shown in Fig. 2 . As shown in Fig. 2 , minor DNA sequence variability (deletions and base exchanges) occurred upstream of the initiation codon of the MCCH gene (ORF MC148R of the MCV-1 prototype virus).
The inferred MCV early promoter consensus sequence AAAAGTGAAAAAATA (25 nucleotides upstream from initiation codon) closely corresponds to the vaccinia virus early promoter consensus AAAAATGAAAAAATA (Davison and Moss, 1989) . All MCV-1 isolates matched the consensus (AAAAGTGAACTTCTA), with the nucleotide differences occurring at positions not important for vaccinia virus early promoter function. Accordingly, it can be predicted that the MCV chemokine is regulated as an early poxvirus gene. The promoters of the MCCH genes of the two MCV-2 isolates had a T 3 G substitution that made the promoter even more vaccinia-like (Fig. 2) .
A number of nucleotide exchanges were also observed within the coding region of two isolates of the MCV-1 variant and two MCV-2 isolates (Fig. 2) . The observed conservative and nonconservative amino acid exchanges are shown in Fig. 3 . Although the MCCH is 12 amino acid residues longer than human macrophage inflammatory protein 1-␤ (hMIP1␤), the deletion of the active site was maintained in all MCV isolates, suggesting that none encode a protein with chemoattractant activity. The canonical cysteine residues of ␤ chemokines (Ben- Baruch et al., 1995) were conserved in all MCV isolates at the amino acid positions 30/31, 59, and Senkevich et al., 1996) . Promoter, initiation, termination, and polyadenylation signals as well as nucleotide exchanges are shown underlined and in bold letters. Nucleotide exchanges in the promoter region are only underlined. Gaps are indicated at the position of nucleotide deletions. Fig. 3) . In contrast to other known ␤ chemokines, the MCCH has two additional cysteine residues at positions 94 and 101 which are also conserved in all 29 MCV isolates analyzed (Fig. 3) . Other general features of the MCCH were preserved in the sequences of all MCV isolates (Fig. 3) including a N-terminal signal peptide of 24 amino acids. It has to be emphasized that no frame shifts and/or truncations were observed within the coding regions of the MCCH genes of any of the MCV isolates investigated. MCV chemokine transcripts were amplified by RT± PCR from MCV mRNA synthesized in vitro by permeabilized MCV-1 virions. The MCV-specific cDNA was synthesized from in vitro transcribed MCV mRNA using a specifically designed primer 5 (Table 1 ). This oligonucleotide primer contains 16 nucleotides of MCV unrelated M13 sequences followed by 25 thymidine residues that can specifically bind to poly(A) tails found in eucaryotic mRNAs. Two additional oligonucleotide primers (primers 3 and 6; Table 1) were designed to bind MCV chemokinespecific sequences from the previously synthesized MCV cDNA. The oligonucleotide primer 3 is complementary to the 5Ј end of the MCCH gene. The oligonucleotide primer 6 binds to M13-specific sequences (Table 1) . As shown in Fig. 5 (lane 4) a distinct PCR product of about 450 bp was obtained (Fig. 5) . To confirm the identity of the amplified DNA fragment, DNA nucleotide sequences of several independent RT±PCR products were determined. The DNA nucleotide sequences of all RT±PCR products were identical with exception of their 3Ј termini and found to be full-length MCCH transcripts. The obtained DNA sequences differed by up to 9 nucleotides in length. One cDNA sequence that is terminated 100 nucleotides downstream of the stop codon and 49 nucleotides downstream of the transcription termination signal is shown in Fig. 6 (cDNA-RNA-in-vitro). Between 40 and 50 nucleotides downstream of the transcription termination signal, all transcripts were terminated consistent with previous studies with vaccinia virus (Yuen and Moss, 1987) . This experiment indicates, that the MCV chemokine gene is transcribed as an early gene in vitro.
(
Transcription of the MCCH gene in human infected skin tissue
After the successful detection of MCV chemokine transcripts as an early MCV gene product in vitro, it was necessary to investigate whether the MCV chemokine transcript is also detectable in vivo. Total RNA was prepared from an MCV-infected skin specimen and analyzed under the conditions described above. The 450-bp RT±PCR product ( Fig. 5 ; lane 5) was similar in size and identical in sequence ( Fig. 6 ; cDNA-RNA-in-vivo) to the previously observed RT±PCR products obtained from in vitro transcribed MCV mRNA. The analysis revealed that the MCV mRNA transcript was terminated 106 and 55 nucleotides downstream of the MCV chemokine stop codon and the termination signal, respectively. This experiment indicates that the MCV chemokine gene is transcribed in skin of MCV-infected patients. 5 . Detection of MCV-1 chemokine transcript by RT±PCR. Analysis of PCR products by agarose slab gel electrophoresis. Lanes 1 and 10: 100-bp ladder molecular weight marker. PCR product obtained from viral DNA using primers 3 and 4 served as positive internal marker (lane 2). Negative internal control in which viral DNA was tested by RT±PCR using primers 5 and 6 is shown in lane 3. The PCR products obtained from cDNA using primers 3 and 6 from in vitro transcribed viral RNA (lane 4), amplification of MCV-1 chemokine transcripts from total RNA derived from an MCV-1-infected tissue specimen (lane 5), and from total mRNA derived from a transfectant cell line (P815-mouse mastocytoma) harboring the MCV-1 chemokine gene (2) (lane 6). Lanes 7 to 9: PCR assays identical to the RNA preparations of lanes 4 to 6 in which the RNA was treated with RNase prior to cDNA synthesis.
The MCCH protein is secreted from mammalian cells
The predicted amino acid sequence of the MCCH suggested the presence of an NH2-terminal signal peptide and the absence of a C-terminal transmembrane region. Therefore, we thought that the protein might be secreted from infected cells. Since MCV cannot be grown in tissue culture, we constructed a recombinant vaccinia virus with the MC148L open reading frame. The cell-free supernatant obtained from BSC-1 cells which were uninfected, infected with vaccinia virus strain WR, or infected with the recombinant virus was collected and analyzed by SDS±polyacrylamide gel electrophoresis and Western blotting with antiserum to a 34-amino-acid MC148L-derived peptide. A protein of 10 kDa was detected only in the supernatant from BSC-1 cell cultures infected with the recombinant virus (Fig. 7) . Preimmune sera of immunized rabbits which served as controls did not recognize MCCH. This indicates that the MCCH was synthesized and secreted in the medium as expected from the predicted protein feature.
DISCUSSION
The detection of interleukin 8 (Bagglioni et al., 1994; Ben-Baruch et al., 1995) was followed by the discovery of a family of polypeptides known as cellular chemokines or intercrines (Miller and Krangel, 1992) . This finding contributed important new knowledge to our understanding of the human inflammatory response. The analysis of the complete genome of MCV (Senkevich et al., 1996) led to the identification of the first known viral chemokine homolog (ORF MC148R) related to the ␤ chemokine family (Miller and Krangel, 1992; Schall et al., 1990) . Recently, Russo and co-workers reported that the genome of Kaposi sarcoma-associated herpesvirus (HHV8) encodes homologs to three cytokines, including two macrophage inflammatory proteins and interleukin 6 (Russo et al., 1996) . The typical arrangement of four cysteine residues within the MCV chemokine sterically favors the disulfide bonding pattern and the general conformation of a chemotactic factor (Ben-Baruch et al., 1995) . However, the absence of 5 of 10 N-terminal amino acid residues in the receptor activation area may indicate an inability to trigger a biological reaction in the target cell while the molecule is still able to bind the receptor. Therefore, an anti-inflammatory activity resulting from competition of the viral homolog with cellular chemokines at the target cell receptor was proposed (Senkevich et al., 1996) . Such a role is supported by a recent report that MCCH block the chemotactic response of monocytes to MIP-1␣ (Krathwohl et al., 1997) . This model assumes that the MCCH gene sequence, including the putative inactivating deletion, is present in independent MCV isolates; that the gene is expressed in skin lesions; and the protein is secreted from mammalian cells. However, due to the fact that MCV cannot be replicated in cell or tissue culture and there is no animal system for propagation of MCV, the conventional virological techniques cannot be employed for the characterization of the MCCH gene product. In the present study, we first demonstrated that the MCV ORF MC148R is present in all viral isolates tested, regardless of their origin. The apparent NH2-terminal deletion was conserved in all genes and no frameshift changing insertions or deletions were observed, despite the occurrence of point mutations within the coding sequences. The single amino acid changes in the MCV-2 chemokine homolog were mostly conservative, suggesting that they are not of functional importance. Nevertheless, the amino acid sequence variation in the two MCV-2 isolates from geographically distant areas (MCV-2-HD-95/7 from Germany and MCV-2-UK-66 from Scotland) were nearly identical.
RT±PCR was used to characterize the MCCH mRNA synthesized in vitro. The fact that the MCCH gene was transcribed by purified MCV particles was consistent with the presence of a consensus early promoter (Davison and Moss, 1989) . Furthermore, all analyzed transcripts ended between 40 and 55 nucleotides downstream of the TTTTTNT early transcription termination signal that was first described for vaccinia virus (Yuen and Moss, 1987) . Neither intermediate nor late classes of mRNA are terminated after that signal. Thus, MCV and vaccinia virus use the same transcriptional regulatory mechanisms, as also predicted from the conservation in MCV of all proteins known to be involved in vaccinia virus transcription (Senkevich et al., 1997) . The RT±PCR technique also permitted us to demonstrate the presence of the MCCH mRNA in an infected skin lesion. Moreover, the length and the sequence of the cDNAs were the same as those obtained for the in vitro mRNA.
Finally, we used vaccinia virus as a surrogate poxvirus to demonstrate that the MCCH can be secreted from mammalian cells. The 10-kDa mass of the polypeptide, experimentally determined from the mobility of markers, closely matched the predicted mass of 9.87 kDa. It will be interesting to determine whether such recombinant vaccinia viruses can inhibit the inflammatory response in the skin of experimental animals.
MATERIAL AND METHODS
Virus and recombinant plasmids
A collection of 29 MCV isolates was obtained from independent MCV-infected individuals and used for the screening of the MCCH gene locus. The recombinant plasmid harboring the specific DNA sequences of the MCV-1 prototype used in this study were described previously (Darai et al., 1986; Bugert and Darai, 1991) . Vaccinia virus strain Western Reserve (WR) was grown in HeLa S3 cells as described elsewhere (Broyles et al., 1988) .
Construction of recombinant vaccinia virus
Recombinant vaccinia virus harboring the MCCH gene was constructed using the method described by Blasco and Moss (1995) . The MCV ORF 148R was amplified from the recombinant plasmid pMCV-1-B-C1 by PCR using primers 3 and 4 ( Table 1 ). The 342-bp amplification product was directly cloned into the TA cloning vector pCRII (Invitrogen). The gene was excised using the restriction endonuclease EcoRI and subcloned into the vaccinia donor plasmid vector pRB21 under the control of the vaccinia virus strong synthetic early/late promoter (Blasco and Moss, 1995) . Orientation of the MCCH gene in the resulting recombinant plasmid pJB133 was determined by BamHI restriction and gel electrophoresis. CV-1 cells were then infected with the F13L deletion mutant vRB12 and transfected with the donor plasmid as described previously (Blasco and Moss, 1995) . After 48 h the cells were harvested by scraping, collected by centrifugation, freeze±thawed three times, and sonicated. Serial dilutions were added to confluent BS-C-1 monolayers, overlaid with medium containing 1% low melting agarose and individual plaques were isolated. The plaque purification was repeated two more times and the virus was amplified in BSC-1 cells as described (Blasco and Moss, 1995) . The presence of the MCCH gene in the purified virus was tested by PCR using primers 3 and 4. The recombinant vaccinia virus containing the MCCH gene was subsequently termed vJJBCC133-2.5.1.
Western blot detection of MCCH
Confluent BSC-1 cells (5 ϫ 10 5 ) were mock infected or infected with 5 ϫ 10 6 PFU of sonicated and trypsintreated recombinant or WR virus in 1 ml of EMEM with 2.5% FBS. After 1 h, the volume of the medium was increased to 3 ml. At 6 h, the medium was removed and 1 ml of EMEM with 0.5% FBS was added to the cells. After an additional 27 h, the medium was collected and clarified by centrifugation. A 30-l sample of infected or uninfected cells was mixed with an equal volume of tricine loading buffer, heated to 96°C for 5 min, and then applied to a Tris±tricine polyacrylamide (16.5%) gel. Proteins contained in the gel were transferred onto a 0.2-m nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) at 150 mA for 90 min in Tris±glycine buffer. The membranes were blocked overnight in 3% dried milk± PBS and incubated with a 1:200 dilution of rabbit polyclonal antipeptide sera for 1.5 h. Subsequent steps followed manufacturer's instructions for the commercially available ECL (Amersham) kit. A 20-s exposure was used. The polypeptide used to raise rabbit polyclonal antiserum was derived from the N-terminal sequence of MCCH (25-LARRKCCLNPTNRPIPNPLLQDLSRVDYQIG-HDC-59) and coupled to KLH (keyhole limpet hemocyanine) prior to immunization of rabbits.
In vitro RNA synthesis by permeabilized virions MCV virions were isolated from MCV lesion material by centrifugation through a 36% sucrose cushion. Vaccinia virions were purified from infected HeLa cells by sucrose gradient centrifugation. The virions were resuspended in 1 mM Tris±HCl, pH 8.0, adjusted to the optical density of 1 OD at 260 nm, and stored at Ϫ80°C.
The in vitro transcription assay is based on a protocol described by Shand et al. (1976) and has been modified for the production of mRNA suitable for RT±PCR. Virus suspension (50 l) (OD 260 ϭ 1) was incubated in a volume of 200 l with in vitro transcription buffer containing 1.0 M Tris±HCl, pH 8.5, 50 mM MgCl 2 , 0.25% 2-mercaptoethanol, 0.05% Nonidet P-40, 20 l of 75 mM phosphoenolpyruvate, 4.0 g pyruvate kinase, 1.0 l RNasin (40 U/l, Boehringer, Mannheim, Germany), 4.0 mM ATP, and 2.0 mM CTP, UTP, and GTP at 35°C for 120 min. For synthesis of radioactively labeled MCV mRNA the reaction was incubated for 180 min and UTP was substituted by 0.2 mM [␣-32 P]UTP (sp act 1±3 ϫ 103 Ci/mmol; New England Nuclear, Dreieich, FRG). Four aliquots (each 20 l) were taken at different times (0, 60, 120, and 180 min), and soluble and core-associated RNA were separated by centrifugation, filtrated on nitrocellulose, and washed three times with 10% trichloroacetic acid, and the incorporated radioactivity was measured in a Beckman scintillation counter. The remaining supernatant was phenol/chloroform extracted and ethanol precipitated in the presence of 3.0 M sodium acetate, pH 5.3. Unincorporated nucleotides were removed over Sephadex G50 columns. The [␣-32 P]UTP-labeled in vitro transcribed MCV mRNA was hybridized to MCV and vaccinia viral DNA and recombinant plasmids harboring MCV viral DNA fragments were immobilized on nitrocellulose membranes. Unlabeled in vitro transcription reactions were treated under the same conditions as described above and used for RT±PCR. Twenty units of RNase inhibitor was added to the RNA sample, and the reaction was treated with 1.0 l (40 U/l) DNase/RNase free.
RNA extraction from MCV-infected human tissue
MCV-1-infected human skin samples were immediately frozen at Ϫ20°C. Total cellular RNA was extracted from five individual MCV lesions by the guanidinium/ cesium chloride method (Glisin et al., 1974; Ullrich et al., 1977) as described by Sambrook et al. (1989) . RNA was screened by RT±PCR as described below.
Polymerase chain reaction and RT±PCR
Oligonucleotide primers used for PCR were synthesized according to the coding sequences of the MCV-1 ORF MC148R and its flanking regions. The properties of all primers used in this study are summarized in Table 1 . PCR was performed using 0.01 fmol of MCV DNA in 50-l volumes containing 50 mM KCl, 10 mM Tris±HCl, pH 8.3, 1±2 mM MgCl 2 , 1.5% Formalin, 200 mol of each dNTP, 1.0 mol of each primer, and 0.5 U of Taq polymerase (Perkin±Elmer). Twenty-five cycles were run in an automated temperature cycling reactor (Perkin±Elmer Geneamp 2400) which provided 30 s of incubation at 96°C and 4 min at 60°C per cycle. A final incubation step at 72°C for 7 min was used to extend all unfinished product. The amplified product was phenol/chloroform extracted and precipitated in ethanol. The DNA nucleotide sequence analysis of the MCCH gene locus was performed using primer 1 (Table 1) , located 130 bp upstream of the initiation codon, and primer 2 (Table 1 ) located 75 bp downstream of the stop codon.
For RT±PCR experiments AMV reverse transcriptase and LA Taq polymerase (TaKaRa-Shuzo Co., Ltd., distributed by Boehringer Ingelheim, Germany) were used. For cDNA synthesis an oligo(dT) primer was designed with an universal M13 primer binding site (primer 5, Table 1 ). For amplification of the MCV chemokine-specific cDNA sequences oligonucleotide primers 3 and 6 (Table 1) were used. Primer 6 contains the universal M13 primer binding sequences incorporated into the oligo(dT) adapter primer (primer 5, Table 1 ). The amplification of the autologous chemokine gene of MCV isolates was performed using primers 3 and 4 (Table 1) . PCR products were analysed by slab gel electrophoresis.
DNA sequence analysis
The DNA sequence of the PCR products in this study was determined with an automated 373``Extended'' DNA sequencer using the standard terminator cycle sequencing technique (Applied Biosystems GmbH, Perkin±Elmer Corp., Germany) using oligonucleotide primers 1 to 3 (Table 1) .
Computer-assisted sequence analysis
Nucleotide sequences were compiled using the ABI sequence navigator software, version 1.2. Nucleotide and amino acid sequences were analyzed using the PCGENE program, release 6.85 (Intelligenetics Inc., Mountain View, CA).
